GSK PLC Updates
GSK PLC has made several announcements in recent developments. The company has acquired IDRx for a substantial amount, expanding its cancer drug pipeline.
Key Acquisition Details
- The acquisition includes the procurement of IDRX-42, a tyrosine kinase inhibitor
- The acquisition amount is undisclosed
Securities Fraud Class Action Lawsuit
GSK is involved in a securities fraud class action lawsuit. Eligible investors who lost money on the company’s securities have the opportunity to lead the lawsuit. Key details include:
- Deadline for lead plaintiff: April 7, 2025
- Eligibility criteria for lead plaintiff are not specified
Research Collaboration Update
GSK has made a payment of $14 million to Zymeworks Inc. as part of a research collaboration. This payment marks a significant milestone in their partnership.